Office of Portfolio Analysis and Strategic Initiatives, Office of the Director, National Institutes of Health; Notice of Meeting, 56775-56776 [07-4932]

Download as PDF Federal Register / Vol. 72, No. 192 / Thursday, October 4, 2007 / Notices pwalker on PROD1PC71 with NOTICES Application: Induction of wound healing through use of CpG oligodeoxynucleotides. Developmental Status: CpG oligonucleotides have been synthesized and preclinical studies have been performed. Inventors: Dennis Klinman and Takahashi Sato (NCI). Patent Status: U.S. Provisional Application filed 06 Sep 2007 (HHS Reference No. E–242–2007/0–US–01). Licensing Status: Available for exclusive or nonexclusive licensing. Licensing Contact: Peter A. Soukas, J.D.; 301/435–4646; soukasp@mail.nih.gov. Collaborative Research Opportunity: The Laboratory of Experimental Immunology of the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize methods of increasing epithelial cell growth. Please contact John D. Hewes, Ph.D. at 301–435–3121 or hewesj@mail.nih.gov for more information. Flexible, Polyvalent Antiviral Dendritic Conjugates for the Treatment of HIV/ AIDS Description of Technology: This technology describes the design and synthesis of flexible, polyvalent, antiviral conjugates of less than 200 kDa for the treatment of HIV/AIDS. These conjugates are mimetic of D1D2-Igatp, a high-molecular-weight (1 MDa) CD4immunoglobulin fusion construct with extreme HIV neutralizing potency. Cryo electron microscopy suggests that the extreme potency of D1D2-Igatp is due to polyvalent presentation of a gp120binding ligand on a flexible scaffold. The current prototype for the technology is a conjugate comprising soluble, two-domain human CD4 covalently linked to a flexible poly(ethylene glycol)-PAMAM dendrimer scaffold. The construct is designed to retain a high degree of flexibility and polyvalence, and, at less than 200 kDa, is similar in size to successful antibody therapeutics currently on the market. Because it retains the key determinants of potency and the human CD4 moieties of D1D2Igatp, this conjugate is expected to have the following unique set of HIV antiviral properties: (1) IC90 infectivity neutralization values in the nanomolar range against HIV primary isolates; (2) lack of susceptibility to viable escape mutations, because the ligand is CD4, and because CD4-independence evolves concomitantly with constitutive exposure of neutralization-sensitive, VerDate Aug<31>2005 16:20 Oct 03, 2007 Jkt 214001 highly conserved coreceptor binding site epitopes; (3) indefinite control of HIV viral replication, without the need for combination therapy, arising from properties (1) and (2); (4) improved HIV viral replication control when used in combination with other Highly Active Antiretroviral Therapy (HAART); (5) improved prevention of seroconversion when used in combination with other HAART shortly following known exposure to HIV. Applications: Novel therapeutics for the treatment and prevention of HIV infection. Development Status: Synthesis and characterization in progress. Inventors: Sriram Subramaniam and Adam Bennett (NCI). Publication: AE Bennett et al. Cryo electron tomographic analysis of an HIV neutralizing protein and its complex with native viral gp 120. J Biol Chem., in press; published online ahead of print June 28, 2007. Patent Status: U.S. Provisional Application No. 60/932,464 filed 31 May 2007 (HHS Reference No. E–213– 2007/0–US–01). Licensing Status: Available for licensing. Licensing Contact: Sally Hu, Ph.D.; 301/435–5606; HuS@mail.nih.gov. Collaborative Research Opportunity: The Laboratory of Cell Biology of the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Flexible, Polyvalent Antiviral Dendritic Conjugates for the Treatment of HIV/AIDS. Please contact John D. Hewes, Ph.D. at 301–435–3121 or hewesj@mail.nih.gov for more information. Monoclonal Antibodies to FusionActive Conformations of GP41 Description of Technology: This technology describes three novel monoclonal antibodies, 2F12, 9C5 and 11B8, which were derived against an HIV gp41 heptad-repeat entry inhibitor that mimics a structure of the HIV envelope protein fusion intermediate. These antibodies recognize the fusionintermediate and six-helix conformations of gp41 and are useful tools for high-throughput screening assays (HTS) to identify novel HIV–1 inhibitors. Since the drugs identified in the assays using these monoclonal are expected to inhibit HIV infection in a different manner than current antiretroviral drugs, these antibodies may serve as valuable tools for screening for new drugs that may have activity against HIV strains that are PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 56775 resistant to currently available antiretroviral drugs. Applications: Research tool. Development Status: In vitro data available . Inventors: Carol D. Weiss and Russell A. Vassell (CBER/FDA). Related Publication: S Jiang et al. A screening assay for antiviral compounds targeted to the HIV–1 gp41 core structure using a conformation-specific monoclonal antibody. J Virol Methods. 1999 Jun;80(1):85–96. Patent Status: HHS Reference No. E– 124–2007/0—Research Tool. Patent protection not being pursued for this technology. Licensing Status: Available for nonexclusive licensing as biological material. Licensing Contact: Sally Hu, Ph.D.; 301/435–5606; HuS@mail.nih.gov. Dated: September 27, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–19649 Filed 10–3–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of Portfolio Analysis and Strategic Initiatives, Office of the Director, National Institutes of Health; Notice of Meeting Notice is hereby given of a planning meeting for the proposed Council of Councils, an external advisory panel to the NIH IC Directors and the Office of Portfolio Analysis and Strategic Initiatives (OPASI). The meeting will be open to the public, with attendance limited to space available. individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Council of Councils Planning Group. Date: November 8, 2007. Time: 8:30 a.m. to 5:00 p.m. Agenda: Among the topics proposed for discussion are: Role of the Council and timeline. Place: National Institutes of Health, Building 31, Conference Room 6, 9000 Rockville Pike, Bethesda, MD 20892. Contact Person: Robert D. Hammond, PhD, Consultant To OPASI, 301–977–9307, bhammond@thehillgroup.com. Any interested person may file written comments with the committee by forwarding E:\FR\FM\04OCN1.SGM 04OCN1 56776 Federal Register / Vol. 72, No. 192 / Thursday, October 4, 2007 / Notices the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number, and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s Web page: https:// opasi.nih.gov/council/ where an agenda and any additional information for the meeting will be posted when available. Dated: September 18, 2007. Alan M. Krensky, Director, Office of Portfolio Analysis and Strategic Initiatives (OPASI). [FR Doc. 07–4932 Filed 10–3–07; 8:45 am] National Heart, Lung, and Blood Institute; Notice of Closed Meeting National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. pwalker on PROD1PC71 with NOTICES BILLING CODE 4140–01–M National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES Name of Committee: National Cancer Institute Special Emphasis Panel; Pediatric Nutrition. Date: October 22, 2007. Time: 3 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6116 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Virginia P. Wray, PhD, Deputy Chief, Research Programs Review Branch, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8125, Bethesda, MD 20892-8328, 301–496– 9236, wrayv@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing 16:20 Oct 03, 2007 Dated: September 27, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–4925 Filed 10–3–07; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4140–14–M VerDate Aug<31>2005 limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Jkt 214001 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Heart, Lung, and Blood Initial Review Group; NHLBI Institutional Training Mechanism Review Committee. Date: November 15–16, 2007. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Admiral Fell Inn, 888 South Broadway, Baltimore, MD 21231. Contact Person: Charles Joyce, PhD, Scientific Review Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7196, Bethesda, MD 20892–7924, 301–435– 0288, cjoyce@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 Dated: September 28, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–4920 Filed 10–3–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselor, NHLBI. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Heart, Lung, and Blood Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, NHLBI. Date: October 29, 2007. Time: 9 a.m. to 4 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsic Avenue, Bethesda, MD 20814. Contact Person: Robert S Balaban, PhD, Scientific Director, Division of Intramural Research, National Institutes of Health, NHLBI, Building 10, CRC, 4th Floor, Room 1581, 10 Center Drive, Bethesda, MD 20892 301/496–2116. Information is also available on the Institute’s/Center’s home page: https:/// www.nhlbi.nih.gov/meetings/index.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program No. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: September 27, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–4930 Filed 10–3–07; 8:45 am] BILLING CODE 4140–01–M E:\FR\FM\04OCN1.SGM 04OCN1

Agencies

[Federal Register Volume 72, Number 192 (Thursday, October 4, 2007)]
[Notices]
[Pages 56775-56776]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-4932]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of Portfolio Analysis and Strategic Initiatives, Office of 
the Director, National Institutes of Health; Notice of Meeting

    Notice is hereby given of a planning meeting for the proposed 
Council of Councils, an external advisory panel to the NIH IC Directors 
and the Office of Portfolio Analysis and Strategic Initiatives (OPASI).
    The meeting will be open to the public, with attendance limited to 
space available. individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Council of Councils Planning Group.
    Date: November 8, 2007.
    Time: 8:30 a.m. to 5:00 p.m.
    Agenda: Among the topics proposed for discussion are: Role of 
the Council and timeline.
    Place: National Institutes of Health, Building 31, Conference 
Room 6, 9000 Rockville Pike, Bethesda, MD 20892.
    Contact Person: Robert D. Hammond, PhD, Consultant To OPASI, 
301-977-9307, bhammond@thehillgroup.com.

    Any interested person may file written comments with the 
committee by forwarding

[[Page 56776]]

the statement to the Contact Person listed on this notice. The 
statement should include the name, address, telephone number, and 
when applicable, the business or professional affiliation of the 
interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's Web 
page: https://opasi.nih.gov/council/ where an agenda and any 
additional information for the meeting will be posted when 
available.

    Dated: September 18, 2007.
Alan M. Krensky,
Director, Office of Portfolio Analysis and Strategic Initiatives 
(OPASI).
[FR Doc. 07-4932 Filed 10-3-07; 8:45 am]
BILLING CODE 4140-14-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.